German biotech firm Morphosys said this week its ABd Serotec division has licensed seven of its diagnostic HuCAL antibodies to Spanish biomarker company Proteomika for use in its Promonitor diagnostic.
Promonitor is designed to determine circulating levels of different drugs and the immune response they trigger in patients.
It plans to launch kits in the second quarter of this year containing the HuCAL antibodies that can help monitor certain biopharmaceutical therapies.